Stocks Health care CRBU
NASDAQ · Health careCaribou Biosciences, Inc. (CRBU)
Caribou Biosciences, Inc. brought in $10M of revenue over the twelve months to June 30, 2026, up 10.0% from a year earlier. It posted a net loss of $103.4M. In fiscal 2025 capital spending exceeded operating cash flow by $112.4M. At June 30, 2026 it held $26.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
What Caribou Biosciences, Inc. does
Caribou Biosciences, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker CRBU.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $11.2M | -$148.1M | -$1.59 | -$112.4M |
| 2024 | $10M | -$149.1M | -$1.65 | -$143.1M |
| 2023 | $34.5M | -$102.1M | -$1.38 | -$104.9M |
| 2022 | $13.9M | -$99.4M | -$1.64 | -$97.4M |
| 2021 | $9.6M | -$66.9M | -$2.11 | -$34.6M |
| 2021 | $12.4M | -$34.3M | -$4.01 | -$33.5M |
Latest SEC filings
What Caribou Biosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026
- August 13, 2026
- July 27, 2026Passive stake (5% or more) SCHEDULE 13G
- June 18, 2026
- June 11, 2026
- June 5, 2026Additional proxy material DEFA14A
- May 7, 2026Quarterly report 10-Q · period to March 31, 2026
- May 7, 2026
- May 1, 2026Form DEFR14A filing DEFR14A
- April 24, 2026
Questions about CRBU
What does Caribou Biosciences, Inc. do?
Caribou Biosciences, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker CRBU.
Is Caribou Biosciences, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $103.4M on revenue of $10M.
How much revenue does Caribou Biosciences, Inc. make?
Over the twelve months to June 30, 2026 Caribou Biosciences, Inc. reported revenue of $10M. That is 10.0% more than a year earlier.
When did Caribou Biosciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026.
Similar companies
Follow CRBU
Get an email when Caribou Biosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow CRBU: get an email when it filesWhere the numbers come from
Financial figures are the values Caribou Biosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.